In Vitro Thrombogenicity Testing of Biomaterials

73Citations
Citations of this article
128Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The short- and long-term thrombogenicity of implant materials is still unpredictable, which is a significant challenge for the treatment of cardiovascular diseases. A knowledge-based approach for implementing biofunctions in materials requires a detailed understanding of the medical device in the biological system. In particular, the interplay between material and blood components/cells as well as standardized and commonly acknowledged in vitro test methods allowing a reproducible categorization of the material thrombogenicity requires further attention. Here, the status of in vitro thrombogenicity testing methods for biomaterials is reviewed, particularly taking in view the preparation of test materials and references, the selection and characterization of donors and blood samples, the prerequisites for reproducible approaches and applied test systems. Recent joint approaches in finding common standards for a reproducible testing are summarized and perspectives for a more disease oriented in vitro thrombogenicity testing are discussed.

Cite

CITATION STYLE

APA

Braune, S., Latour, R. A., Reinthaler, M., Landmesser, U., Lendlein, A., & Jung, F. (2019, November 1). In Vitro Thrombogenicity Testing of Biomaterials. Advanced Healthcare Materials. Wiley-VCH Verlag. https://doi.org/10.1002/adhm.201900527

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free